Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

GUB014295 is a long-acting amylin analog currently being evaluated in an early-stage study. It has been designed to target receptors linked to appetite control, mimicking the effects of amylin ...

The effects of various agents targeting these gastrointestinal peptide systems, as shown in preclinical studies, are compared in Table 1. Enough experience from large clinical trials has been ...